Key points are not available for this paper at this time.
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has been approved by the FDA to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease (CVD) and either obesity or overweight.
A Mon, study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: